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Abstract 
Background: Carboplatin remains a first-line agent in the management of epithelial 
ovarian cancer (EOC). Unfortunately, platinum-resistant disease ultimately occurs in 
most patients. Using a novel EOC cell line with acquired resistance to carboplatin: 
PEO1CarbR, genome-wide micro-array profiling identified the cyclin dependent 
kinase inhibitor p57Kip2 as specifically down-regulated in carboplatin resistance. 
Presently, we describe confirmation of these preliminary data with a variety of 
approaches. . 
Methods: Cytotoxicity testing (MTT) and cell cycle blockade assessed drug 
responsiveness. Methylation specific PCR (MSP) and pyrosequencing identified sites 
of promoter methylation in p57Kip2. SiRNA to p57Kip2 was used to look at the changes 
in apoptosis of carboplatin treated EOC cells. EOC tissues (20cases) were assessed for 
mRNA levels of p57Kip2.  
Results: Carboplatin-resistance was reversed using 5-aza-cytidine in vitro. Promoter 
methylation sites and preferential sensitivity to seliciclib were seen in PEO1CarbR 
cells. Silencing p57Kip2 decreased the apoptotic response to the effects of platinum but 
produced sensitisation to seliciclib. EOC biopsies indicated an association of high 
levels of p57Kip2mRNA with complete responses to chemotherapy and improved 
outcome..  
Conclusion: We conclude that p57Kip2 is a candidate biomarker of platinum 
sensitivity/ resistance in EOC and such cases may show preferential response to the 
CDK inhibitor seliciclib. 
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Introduction: 
 
p57Kip2 is a member of the CIP/KIP family of cyclin dependent kinase inhibitors 
(CDKI). Each member of this family possesses a conserved domain at their N-
terminus called the CDK binding-inhibitory domain, unlike INK4 family members 
which are characterized by four tandem repeats of an ankyrin motif (Beretta et al. 
2005). In humans, the p57KIP2 gene is situated on chromosome 11p15.5 in a cluster of 
imprinted genes such as IGF-II and H19 (Beretta et al. 2005; Kim et al. 2005; Roeb et 
al. 2007). The gene is associated with a high frequency of heterozygosity loss in 
human cancers and functions as a CDKI via binding to cyclin E-CDK2 complexes, 
leading to inhibition of G1 to S phase progression. Cyclin E-CDK2 is essential for 
pRb phosphorylation and subsequent gene transcription by E2F. The action of p57Kip2 
on the cyclin E-CDK2 complex promotes cell cycle exit and cell differentiation. 
Differentiation signals have been shown to induce accumulation of p57KIP2 mRNA 
(Roeb et al. 2007). P57Kip2 plays a major role in embryogenesis predominantly in 
early organogenesis, with ubiquitous expression in the whole embryo, which 
decreases along with increased embryo development (Beretta et al. 2005).  It is the 
only CDKI associated with normal embryonic development, with loss of expression in 
mouse embryos leading to defective proliferation in lens and cartilage and 
developmental defects in several tissues and increased postnatal lethality (Zhang et al. 
1998).  Deficiency of p57Kip2 in the mouse leads to organomegaly with abdominal 
wall defects, increased apoptosis, delayed differentiation during development, 
immaturity of some tissues, severe growth retardation and placentomegaly (Kim et al. 
2005). Loss of functional p57Kip2 is also a common feature of rhabdomyosarcoma, 
even though it is not a dominantly acting transforming event (Roeb et al. 2007) and 
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has also been reported for breast cancer, suggesting its role as a putative tumour 
suppressor gene (Larson et al. 2008).  
 
Cell cycle dysregulation is a feature of many cancers, including EOC (D’Andrilli et 
al. 2004). Moreover, dysregulation of cell cycle components seems specific for certain 
histological types of epithelial ovarian cancer (EOC). Serous EOC is the most 
commonly observed subtype of this disease with a poorly understood molecular 
aetiology. Overexpression of the CDKi  p21Cip1/Waf11 has previously been shown to be 
associated with early stage serous tumours. Overexpression of p53 and cyclin E and 
reduced expression of p27Kip1 and p21Cip1/Waf1 is associated with increasing tumour 
grade (Bali et al. 2004). There are isolated reports indicating lower p57Kip2 protein 
level in EOC tissue from patients with a poor prognosis (Rosenberg et al. 2001).  
 
 Previous work in our laboratory has involved the generation of novel drug 
resistant models of EOC as part of an ongoing program to understand the basis for 
chemoresistance in this disease. An initial microarray analysis of the human PEO1 
human EOC line and novel drug resistant variants revealed low levels of the gene 
p57Kip2 as a consequence of carboplatin resistance. Further, methylation reversal using 
demethylating agents suggested a mechanism of gene silencing underlying the 
reduced expression of p57Kip2 seen in carboplatin resistant cells. We have further 
examined this initial finding using qPCR analysis, western immunoblotting of the 
same cell lines, chemosensitivity testing and analysis of freshly extracted ovarian 
cancer tissue for mRNA levels of p57Kip2 with assessment of clinico-pathological 
features.  
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Materials and Methods: 
Cell Lines and Culture Conditions: 
The human ovarian cancer cell line PEO1 (kindly provided by Dr F Balkwill, 
formerly of ICRF, London) was grown in RPMI-1640 medium (Sigma Aldrich, 
Poole, UK) supplemented with 10% heat inactivated foetal calf serum and 2mM 
Glutamax. All cell culture reagents were obtained from Sigma (Poole, UK) unless 
stated otherwise. The ovarian carcinoma cell line PEO1 (parental) was cultured as a 
monolayer in RPMI-1640 medium and supplemented with 10% foetal calf serum 
(FCS, heat inactivated; Invitrogen, Paisley, UK) and maintained at low passage 
number.  The drug resistant variants PEO1CarbR (carboplatin resistant) and 
PEO1CisR (cisplatin) were derived by step-wise incubation of the chemotherapeutic 
agent over a number of weeks. The maintenance dose for PEO1CisR was 1 µM 
cisplatin and for PEO1CarbR 2 µM carboplatin. These cell lines have previously been 
described (Coley et al. 2006).  
 
Cytotoxic Drugs 
Cisplatin and carboplatin (Sigma, Poole, UK) was dissolved as a stock solution in 
sterile 0.9% saline and stored at -20o C until use. 5’-aza-2’ deoxycytidine (obtained 
from Sigma Aldrich, Poole, UK) was made up in sterile distilled water and stored at -
20o C in aliquots prior to use in experiments. Seliciclib was obtained from Cyclacel 
Ltd (Dundee, Scotland, UK) and from Selleck Chemicals (Texas, USA), made up in 
DMSO and stored as frozen aliquots. 
 
Drug treatment of cells for methylation reversal 
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For the experiments that looked at the effects of demethylation on platinum sensitivity 
and protein expression levels of p57Kip2, prolonged exposure of demethylating drug 
was used for all cell lines. The cultures were grown up for 4-5 passages in the 
presence of 5’-aza-cytidine at a dose of 1µM for 5 days followed by Trichostatin A 
200nM for 2 days (modified from the protocol described by Syed et al. 2006), as 
repeated dosing with higher doses gave rise to pronounced growth arrest and loss of 
viability, particularly evident for the parental cell line. Note that the carboplatin 
resistant cells were not treated with their maintenance dose of carboplatin during this 
time period. These cells were then used in the MTT assay as shown in Figure 1C. 
 
Cytotoxicity Testing using the MTT Assay 
Cells for cytotoxicity testing were seeded into 96-well plates and allowed to attach 
and equilibrate for 24h in a humidifying incubator at 37oC, 5% CO2. They were then 
treated with various concentrations of drug over 2-3 log orders of concentration and 
left for 72h to allow for approximately 3-4 doublings (approximately 10-fold increase 
in control cell number) over the duration of the drug exposure. Drugs were diluted in 
tissue culture medium containing 10% FCS. Control cell wells were treated with an 
aliquot of drug-free tissue culture medium. Cell viability was determined by addition 
of 4x10-4 mg MTT (thiazoyl blue tetrazolium bromide; Sigma Aldrich, Poole, UK) for 
4h at 37o C. Wells were aspirated to remove the medium and the resulting formazan 
crystals solubilized in 200µl DMSO and the absorbance read at 570nM. The 
absorbance of the formazan product obtained for drug-treated cells was calculated as a 
fraction of that for the untreated control wells. Growth curves were constructed using 
PRISM software and results expressed as IC50 values i.e. dose of drug causing a 50% 
reduction in cell viability.   
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Assessment of cell cycle perturbations following seliciclib treatment of ovarian cancer 
cells: 
Cells were seeded in culture flasks, and incubated for 24h, before treatment with 
seliciclib (25 µM) for 48h. This corresponded to the cells being in early exponential 
phase of growth, approximately 30-40% confluent. At the end of the treatment period, 
cells were removed by trypsinization, centrifuged and the pelleted cells washed in 
PBS and resuspended in ice-cold 70% ethanol in PBS (added slowly whilst vortex 
mixing).  Samples were left at 4°C for at least 24h.  After washing in PBS, cells were 
stained in 5µg/ml propidium iodide and 1mg/ml Ribonuclease A for at least 30mins at 
37°C in the dark.  Fluorescence at 575 nm (FL3) was measured on a Beckman-
Coulter Epics XL  flow cytometer. Cell cycle phases were evaluted using the Multi-
Cycle software program (Beckman Coulter). 
 
Assessment of apoptotic response following silencing of p57KIP2 
Cells were cultured in 6-well plates prior to transfection with siRNA against p57KIP2 
(obtained from Dharmacon, ThermoFisher UK, Epsom, UK). The process was carried 
out according to manufacturer’s instructions and cells were left to grow for 72h, using 
appropriate controls. After this time, cells were harvested and seeded into 25cm2 
flasks to approximately 40% confluence. After attachment, the cells were then treated 
with various doses of carboplatin and with seliciclib for a period of 48h. The doses of 
drug are indicated in the appropriate legend. Cells were then harvested and subjected 
to the Annexin V assay combining with propidium iodide according to manufacturer’s 
instructions (CN Biosciences, Beeston,UK). Samples were then subjected to flow 
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cytometry using FL1 for FITC conjugated Annexin and FL3 for propidium iodide on 
the Coulter EPICS flow cytometer. 
 
DNA isolation: 
DNA was extracted from cell lines with and without treatment with the demethylating 
agent 5-Aza-2’deoxy-cytidine 5µM and with Trichostatin A 200nM for successive 
passages, as described above. This was carried out using the GenElute genomic DNA 
kit (Sigma Aldrich, Poole, UK) according to manufacturer’s instructions.  
 
Methylation specific PCR MSP: 
MSP was carried out using 1µg of genomic DNA with bisulphite modification using 
the EZ DNA methylation kit (Zymo Research; obtained from Cambridge Biosciences, 
Cambridge, UK) according to manufacturer’s instructions. For each assay set up a 
control Universal methylated DNA standard (Zymo Research; Cambridge 
Biosciences) was also taken through the process to ensure that bisulphite conversion 
was complete. Primers were designed using the MethPrime program. The PCR for the 
p57KIP2 CpG island was performed using HotStart Mastermix (Qiagen) using a 
thermal cycler with the following protocol:   
95oC for 15min; 40 cycles of : 95o C for 30s, 52o C for 30s, 72o C for 30s, for the U 
(unmethylated sequence)  and 
95o C for 15min; 40 cycles of  95o C for 30s,  59o C for 30s and 72o C for 30s for the 
M (methylated sequence) 
 
The sequences for the primers (U unmethylated; M methylated) were as follows: 
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   Left M primer   TGTAGTTCGCGGTTTAGTTTTTC 
   Right M primer ATCCACGATAAAACGTCTTATCG 
   Product size: 114 bp 
 
   Left U primer    TTTGTAGTTTGTGGTTTAGTTTTTT 
   Right U primer   ACATCCACAATAAAACATCTTATCA 
   Product size: 118 bp 
 
PCR reactions were carried out on at least 3 separate occasions and the products then 
visualised using 0.8% agarose separation with TAE buffer with ethidium bromide 
staining and transillumination. 
 
DNA methylation analysis using Pyrosequencing 
Two micrograms of DNA was bisulfite-converted using Qiagen Epitect Bisulfite 
Conversion kit and following the manufacturer’s protocol. The bisulfite-converted 
DNA was eluted from the column to 40µl final volume. For pyrosequencing PCR, 2µl 
of the bisulfite-converted DNA was used in a final 50µl reaction volume. The PCR 
cycle used was: 950C for 15min; 50 cycles of: 950C for 30s, 600C for 30s, 720C for 
30s and 720C for 5min. The Pyrosequencing was carried out using the Biotage 
PSQ96MA pyrosequencer. The primers used were: 
Forward Primer: 5’AGGGGAGGGTTGATAGTTA3’ 
Biotinylated Reverse Primer:Bio5’CTAAAATTACCACTTCCAACAAAACATACC 
Sequencing Primer: 5’GGGGAGGGTTGATAGTTAT 
The primers were designed using Pyromark Assay Design Software 2.0 to match the 
region targeted by MSP primers. The primer design was targeted from 1301 to 1700 
bases of the UCSC Genome Browser March 2006 (NCBI36/hg18) annotated CpG 
Island191. The final primers selected had a score of 77 and were passed through the 
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software quality control. The PCR product size was 117bp. The sequencing primer 
covered 17 target polymorphisms/CpG sites. 
 
Western Immunoblotting: 
Whole cell lysates were obtained by trypsinizing the monolayer of adherent cells and 
washing with PBS at 4oC. Cell pellets were then subjected to osmotic rupture in 
hypotonic detergent based buffer (1mM PMSF, NaVO4, aprotinin and leupeptin as 
protease inhibitors, 150mM NaCl, in 50mM Tris buffer, 0.2% SDS, 1% NP-40, pH 
7.5) and 50µg of protein/sample electrophoresed on SDS-PAGE gels with subsequent 
transfer blotting. Membranes were incubated overnight at 4°C with primary antibody.  
After washing, membranes were incubated with a secondary horseradish peroxidase 
(HRP) -linked appropriate species antibody preparation at room temperature for 1h 
followed by chemiluminescence for visualization. Following the probing of each 
membrane with the primary antibody, the membrane was stripped and reprobed using 
an actin antibody to act as a loading control.  
 
Clinical samples and correlation with outcome 
Clinical cases of epithelial ovarian cancer were obtained by informed consent by the 
Section of Gynaecological Oncology and by local ethical committee approval, St 
Luke’s Cancer Centre, Royal Surrey County Hospital, Guildford, Surrey, UK. In each 
case, the diagnosis and presence of adequate tumour representation in the specimen 
was confirmed by histopathological analysis. The histological classification for the 
samples was shown to be: serous (13 cases); clear cell, including those with mixed 
endometrioid histology (1 + 2 cases); mixed Mullerian tumour (1 case); endometrioid 
(2 cases). Since all these women underwent primary surgery at the time of sample 
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collection, they then received 6 cycles of post-operative chemotherapy which included 
combination carboplatin and paclitaxel or single agent carboplatin only depending on 
their performance status. Follow-up and mature data including response to treatment, 
disease free interval and overall survival is also recorded.  Assessment of response to 
treatment included clinical examinations, serum CA 125 levels and CT (computerised 
tomography) scans when indicated. Patients were classified as complete, partial and 
non-responders based on the above three criteria which in turn depended on the bulk 
of residual disease following surgery. Minimal residual disease with normal CA 125 
indicated a complete response. A measurable reduction in disease by 30% or more on 
clinical and radiological examination constituted a partial response. Progression on 
treatment or relapse within 6 months suggested a non-response. 
 
 
Collection and RNA extraction of ovarian cancer biopsies 
Tissue was obtained at first laparotomy prior to chemotherapy and then rapidly frozen 
at -80°C for short term storage prior to extraction. The frozen biopsies in RNALaterTM 
solution were thawed on ice and preservation fluid aspirated. RNA was isolated using 
the RNeasy method (mini-column procedure; Qiagen Ltd.) with sample lysis using the 
TissueLyser (Qiagen Ltd.). The quality of the resulting RNA was checked with an 
Agilent 2100 Bioanalyser using an RNA NanoLabchip® according to the 
manufacturer’s instructions (Agilent Technologies UK Ltd, Stockport, Cheshire, UK). 
The RNA was diluted with RNase free water and quantified using the Nanodrop 
spectrophotometer (Nanodrop Technologies Inc.). Following verification of the 
quality of RNA extracted, 19 samples were deemed suitable for further analysis.  
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Real-time-PCR for p57Kip2 in ovarian cancer cell lines and clinical biopsies of EOC 
cDNA was synthesised from 2 µg of total RNA. PCR was performed in an ABI 
PRISM 7700 Sequence Detection System. (Applied Biosystems) using the dye 
SyberGreen q-PCR mastermix (Qiagen, Crawley, UK). Primers for p57Kip2 were 
obtained from SuperArray (Tebu-Bio, Leicester, UK) with gene identification of 
CDKN1C (NM_000076). Primers for actin were obtained from Invitrogen (Paisley, 
UK). Sequences were: Forward: 5’-GCATCCACGAAACTACCTTC-3’;  
Reverse: 5’-CAGGAGGAGCAATGATCTTG-3’. 
For q-PCR reactions, 1.5mM MgCl2 was used for all primers (p57Kip2 and actin) and 
the cycling conditions used were: 40 cycles 95oC for 30s, 58oC for 30s and 72oC for 
40s. Fold inductions were calculated using the formula 2-(∆∆Ct), where ∆∆Ct is the ∆Ct 
(p57
Kip2
)-∆Ct (actin) and Ct is the cycle at which the threshold is crossed. 
 
Statistical analysis 
Expression levels of mRNA for p57Kip2   of the groups of samples split into categories 
which can be described as CR (complete response) PR (partial response) and NR (no 
response) were assessed using a one way ANOVA using Minitab.  The CR group was 
compared with the PR and NR group combined due to the small sample size for the 
latter group. The survival times of the different groups were compared using a log 
rank test using SPSS Version 12  software. Other t-tests were performed to compare 
IC50 doses obtained from dose response curves and these are quoted as appropriate. 
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Results 
Cell lines 
We have previously derived a novel cell line with acquired resistance to carboplatin, 
PEO1CarbR, from the PEO1 parental cell line, as  described (Coley et al.2006). We 
have also included the PEO1CisR (cisplatin resistant variant) for comparison in some 
experiments.  
 
p57Kip2 is epigenetically down-regulated in carboplatin-resistant EOC cells  
To seek genes differentially expressed between parental and drug resistant cell lines, 
we performed an initial microarray expression analysis screen (data not shown). We 
observed a marked reduction in p57Kip2 expression in the PEO1CarbR cells and thus 
set about confirming the protein expression and mRNA levels.. We performed 
quantitative PCR (qPCR) and western blot analysis of p57Kip2 expression in the PEO1 
parental, cisplatin-resistant and carboplatin-resistant cell lines. These experiments 
showed that p57Kip2 mRNA (and protein) levels were greatly reduced in PEO1CarboR 
relative to the parental PEO1 cells (Figure 1A and 1B). For PEO1CisR cells we saw 
that expression of p57kip2 levels fluctuated but generally the levels were similar or 
higher than the parental PEO1 cell line. 
 
Demethylation increases p57kip2 expression in carboplatin- resistant cells 
The initial microarray assay incorporated a pre-treatment step with aza-cytidine and 
zebularine (both demethylating agents) for comparison of gene expression levels with 
untreated cells. We saw evidence of unmasking of the p57kip2 gene expression levels 
In order to corroborate this intitial observation we tested whether treatment with 5-
aza-2’deoxy-cytidine restored p57kip2 protein expression levels in the cell line panel. 
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We demonstrated that at the protein level demethylation treatment can unmask the 
expression of p57kip2 in the PEO1CarbR line, with no significant effect being seen for 
the parental or PEO1CisR line, as shown in Figure 1A 
 
Drug sensitivity of PEO1 lines and effects of demethylation treatment to 
carboplatin and seliciclib 
Given the association of p57kip2 with CDK2 and cyclin E we considered the use of a 
selective CDK2 inhibitor drug as a possible treatment strategy in p57kip2 deficient 
cells. Using the MTT assay with continuous drug exposure (72h) we saw that 
PEO1CarbR cells showed preferential sensitisation to seliciclib in comparison to 
PEO1 parental and PEO1CisR cells based on IC50 values: PEO1 26.4µM (-/+ 3.51), 
PEO1CisR 33.0 µM (-/+ 2.71) and PEO1CarbR 16.0 µM (-/+ 2.06), p <0.005 (using a 
one-tailed paired test) comparing IC50 value for  PEO1CarbR with either PEO1 or 
PEO1CisR. Dose response curves for the PEO1 lines treated with seliciclib are shown 
in Figure 2A.  
 
We then used a similar epigenetic reversal treatment protocol as in western blotting 
experiments (Figure 1A) and assessed drug sensitivity following this. 5-Aza-2’deoxy-
cytidine had a negligible effect on sensitivity to either carboplatin or seliciclib in 
parental PEO1 cells (IC50 values not changed by more than 10%, data not shown). For 
the time period we used the epigenetic reversal protocol (c.4 weeks), the drug resistant 
variant maintained a drug resistant phenotype in parallel cultures, under standard 
culture conditions (in the absence of the demethylating agent), indicating that the 
resistance phenotype was stable for the study period in the absence of the inducing 
agent (carboplatin). As depicted in Figure 2B, the IC50 values (µM) following 
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treatment of cells with continuous exposure to carboplatin were as follows giving the 
mean and (standard deviation) for at least 3 separate replicate analyses: PEO1 22.7 
(7.8), PEO1CarbR 94.3 (26.4), PEO1CisR 98.7 (16.7). In addition, for the 
PEO1CarbR-demethylated cells the level of carboplatin resistance was reduced with a 
shift in IC50 down to 49.2 µM (p = 0.0055 using a one-tailed paired test). In the same 
experiments we saw that the level of seliciclib sensitivity was reduced in the 
PEO1CarbR-demethylated cells going from 16.0 to 23.3 µM (p = 0.016 using a one-
tailed paired test) following unmasking of p57kip2. 
 
 
Carboplatin –resistance associated with p57Kip2 silencing gives rise to collateral 
sensitivity to the CDK inhibitor seliciclib which is shown by a prolonged S-phase 
Treating asynchronous cultures of the PEO1 panel of cell lines with a 25µM dose of 
seliciclib gave rise to cell cycle perturbations, as seen in Figure 3, with the biggest 
differences being seen for PEO1CarbR in terms of the decrease in G1 (p value 0.005 
and 0.003 for PEO1CarbR and PEO1CisR, respectively using a one-tailed paired 
test)) and concomitant increase in S-phase : p value 0.03 for PEO1CarbR, PEO1 0.26 
and PEO1CisR 0.24,  comparing control and treated cells using a one-tailed paired t 
test). Statistical analysis of the sub-G1 populations of cells comparing untreated 
controls and following seliciclib treatment produced p values that were for PEO1 
0.05, PEO1CarbR 0.06 and for PEO1CisR 0.15 (using a one-tailed paired test). Thus, 
the S-phase change following treatment emerged as the best indicator of sensitivity to 
seliciclib. AnnexinV experiments using flow cytometry were also carried out and 
support the finding for a greater apoptotic response seen for seliciclib treated 
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PEO1CarbR cells compared with PEO1 cells (data not shown), in line with the 
cytotoxicity data. 
 
Detection of methylation specific site in p57kip2 in carboplatin sensitive and-
resistant ovarian cancer cells 
Reversal of p57Kip2 silencing by 5-aza-2’deoxy-cytidine implies that methylation-
dependent transcriptional silencing may underlie the reduced expression in 
PEO1CarboR. To directly address this possibility, we performed methylation specific 
PCR (MSP) analysis of the CpG island in the 5’ region of the p57KIP2 gene. Following 
PCR the resulting products were run on an agarose gel and visualized using ethidium 
bromide staining with transillumination.  For the PEO1CarbR cells the level of 
methylated (M) p57kip2 was shown to be significant, with a very small band seen for 
the unmethylated (U) DNA, whereas for the PEO1 parental cells the predominant 
form of p57kip2 was seen to be of the unmethylated form. Treatment with aza-cytidine 
revealed a marked increase in the unmethylated form of p57kip2 for PEO1CarbR cells, 
Figure 4A. This corroborates the data obtained for protein expression as shown in the 
western blotting data, Figure 2A. Using the sensitive method of pyrosequencing, we 
were able to detect the exact level of methylation at each CpG location along the 
sequence positions 1361-1445 which matches well with the sequence we examined 
using MSP (1407-1520) (Figure 4B). The level of methylation for PEO1CarbR was 
shown to be significantly higher than for PEO1, p = 0.026 and for PEO1CisR the 
levels of methylation were not significantly different from the parental cell line (p 
value 0.285 using a paired t-test, data not shown). 
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Silencing of p57Kip2 results in a decreased apoptotic response to platinum 
Data shown in Figure 5A indicate the changes in apoptotic effects seen in at 48h post-
treatment in drug treated EOC cells following silencing with siRNA to p57Kip2. All 
experiments were carried out at least 3 times on PEO1 parental cell lines (not shown). 
Statistically significant decreases in apoptotic responses to carboplatin and increases 
in apoptotic response to seliciclib were seen in silenced versus control cells, see 
legend Figure 5A, which indicates cells in the viable region of the quadrant plot for 
the annexin assay (lower left), expressed as a percentage of the untreated control cell 
viability (considered as 100%). Figure 5C shows the consistent lack of apoptosis 
induction for the p57kip2 silenced cells over the dose range of 100-200µM carboplatin 
treatment for 48h. Comparison of control and transfected drug treated cell viabilities 
was carried out using the paired t-test (indicated in the figure legend). Similar 
experiments were carried out on SKOV-3 parental cells and the effects of p57kip2 
silencing gave very similar (statistically significant) shifts in sensitivities to 
carboplatin and to seliciclib as seen for transfected PEO1 cells (data not shown). 
 
Clinical samples of EOC showed down-regulation of p57Kip2 mRNA which was 
associated with worse outcome 
Statistical analysis of the data obtained from the q-PCR analysis of RNA obtained 
from surgical samples of ovarian cancer showed a significant increase in survival for 
those cases where there was a complete response (CR) to platinum-based 
chemotherapy compared with the other cases. A one-way ANOVA analysis for  
comparing p57Kip2 mRNA expression with a complete response compared with partial 
and non-responders combined within the entire data set, which includes all the 
histological types, showed a significant difference : p value of 0.034, Figure 6. In the 
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data set obtained there was a significant increase in survival time (measured in months 
and for all histological types) associated with response to therapy ( p = 0.002 using a 
one-way ANOVA (data not shown).  
 
Discussion 
There is increasing evidence that acquired resistance to cytotoxic chemotherapeutic 
drugs is driven by epigenetic rather than genetic mechanisms (Glasspool et al. 2006). 
Moreover, anticancer drug resistance is probably better described as a polygenic 
condition / state whereby many factors may be operative in one patient. The 
inactivation of many genes with important functions, such as tumour suppressor 
genes, has shown that aberrant methylation plays an important role in human 
carcinogenesis. The data we provide in the current study explore this further in terms 
of evolution of drug resistance in difficult to treat cancers – notably EOC.  
Moreover, we propose that p57Kip2 plays a pivotal role in the chemo-responsiveness of 
EOC particularly in relation to platinum containing regimens – specficially for 
carboplatin. Methylation of p57KIP2 has been implicated in a number of malignant 
conditions e.g. lung, breast and malignant mesotheliomas (Kobatake et al. 2004). 
However, to our knowledge, the role of this gene in anticancer drug resistance has not 
been reported until now. 
 
Our study has made use of a panel of EOC lines with resistance to carboplatin, but we 
also used a cisplatin-resistant counterpart in parts of the study. Our study clearly 
shows that the association of drug resistance with down-regulation of the p57kip2 gene 
and collateral sensitivity to the CDK2 inhibitor seliciclib was seen exclusively for the 
carboplatin resistant cell line in our panel. Notwithstanding, we see cross-resistance to 
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carboplatin in the PEO1CisR cisplatin resistant line – but this is in the absence of 
p57kip2 downregulation and without concomitant relative sensitivity to seliciclib. The 
development of resistance to cancer chemotherapeutic drugs can result in cell lines 
with mixed and complex resistance phenotypes – even using the same class of 
chemotherapy drug as an inducing agent, such as platinum agents (Song.et al. 2004). 
A study by Vlachos et al. (2007) indicated the importance of p57Kip2 in the 
commitment of drug treated HeLa cells to drug induced apoptosis and lends support to 
the role of this CDKI in response to anticancer drug therapy. Using an inducing 
transfection system it was shown that selective expression of p57KIP2sensitised cancer 
cells to the mitochondrial pathway of apoptosis following treatment with cisplatin, 
etoposide and staurosporine. Interestingly, the mechanism was shown to operate 
separately from any activity of p57Kip2 relating to its CDK inhibitory activity 
(although the sensitivity to seliciclib, at least in this system, suggests a CDK-
dependent mechanism). Thus, this study corroborates the findings of the current study 
that equates a reduced expression of p57Kip2 with a more chemoresistant phenotype. 
Indeed, we did see a reduced sensitivity of p57kip2 silenced cells to the effects of 
cisplatin, as well as to carboplatin (data not shown). 
 
Our findings that ovarian cancer cells with silenced p57Kip2 are more sensitive to the 
effects of the CDK inhibitor seliciclib are in keeping with the findings of Ma and 
Cress (2007). MDA-MB-231 cells deficient in p57Kip2 (using shRNA) were 
significantly more sensitive to the effects of the CDK2 inhibitor BMS-387032 in a 
similar manner to that seen for PEO1CarbR cells treated with seliciclib. In the same 
study it was shown that exogenous expression of p57Kip2 cells led to a decreased 
fraction of cells in the S-phase and repression of E2F1 transcription following 
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treatment with BMS-387032. This is in line with our findings that p57Kip2 deficient 
PEO1CarbR cells are sensitised to the effects of seliciclib as shown by an enhanced 
apoptotic response and cytotoxicity. 
 
The CDKIs have been implicated in the pathogenesis of ovarian cancer – with the 
expression of p27Kip1, but not p21Waf1 being associated with response to chemotherapy. 
Masciullo et al. (1999) showed that p27Kip1 positivity was a strong predictor of 
survival, and was strongly associated with response to chemotherapy in those patients 
who were optimally debulked at the time of their first surgery. However, the 
expression of p21Waf1 was not associated with response to platinum agents or other 
chemotherapy in a group of 120 patients with EOC (Levesque et al. 2000). The 
present study shows in vitro evidence that measurement of p57Kip2 may be a useful 
prognostic indicator in EOC. 
 
As well as genes such as methylation of p57Kip2 it is likely that many other events will 
contribute to the process of drug resistance in a given case of EOC. This is in line 
with studies published by other groups that have used clinical biopsies of EOC to 
monitor changes in CpG islands as a marker of disease progression (Wei et al. 2002). 
Serum or plasma from cancer patients often contains identical DNA changes to those 
present in the tumour and can thus provide a means for monitoring epigenetic changes 
within an individual tumour in a surrogate sample. We have recently completed a 
study involving matched blood and tissue from patients with EOC who were clearly 
defined into two cohorts of either relapsing or non-relapsing. We have gone on to 
measure the serum and plasma DNA for another gene - associated with the polo-like 
kinases and G2 checkpoint control - in those patients and have seen a statistically 
Running title: 
p57Kip2 status predicts carboplatin sensitivity 
 22 
significant association between methylation status and relapse (Syed et al. 2011). As a 
continuation of the study presented herein our future studies involving p57Kip2 will 
involve measurement of methylated p57KIP2 DNA in tumour tissue and matched serum 
from a large cohort (>200) of ovarian cancer patients. We therefore plan to explore 
the utility of methylated p57KIP2 DNA as a prognostic indicator in ovarian cancer. 
Moreover, our data suggest that p57Kip2 could be used as a marker of sensitivity to the 
cell cycle inhibitor seliciclib. 
 
In conclusion, we present data that contribute to our understanding of drug resistant 
EOC and support the notion that this process can be explained on the basis of 
epigenetic modification, involving the CDKI p57Kip2. Moreover, our approach will 
help in the identification and evaluation of new prognostic markers for the 
management of EOC. 
 
Conflict of Interest 
There are no competing financial interests in relation to the work described in this 
manuscript concerning any authors. 
 
Acknowledgement: 
We would like to thank the GRACE charity UK (registered charity number 1109997) 
for support provided to make this study possible. 
 
 
 
 
Running title: 
p57Kip2 status predicts carboplatin sensitivity 
 23 
References: 
Beretta C, Chiarelli A, Testoni B, Mantovani R. Guerrini L (2005). Regulation of 
the cyclin dependent kinase inhibitor p57kip2 by p63. Cell Cycle 4: 1625-1631, 
2005. 
 
Coley HM, Shotton CF, Ajose-Adeogun A, Modjtahedi H, and Thomas H (2006). 
Receptor tyrosine kinase inhibition is effective in chemosensitising EGFR-
expressing drug-resistant human ovarian cancer cell lines when used in 
combination with cytotoxic drugs. Biochem Pharmacol 72: 941-948. 
 
D’Andrilli G, Kumar C, Scambia G and Girodano A (2004). Cell cycle genes in 
ovarian: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 10: 
8132-8141. 
 
Glasspool RM, Teodoridis JM, Brown R (2006). Epigenetics as a mechanism 
driving polygenic clinical drug resistance.Br J Cancer 94:1087-92. 
 
Kim ST, Lee SK, Gye MC (2005). The expression of the cyclin dependent kinase 
inhibitor p27kip1 and p57kip2 in the mouse placenta and human choriocarcinoma 
JEG-3 cells. Placenta 26: 73-80. 
 
Kobatake T, Yano M, Toyoka S, Tsukuda K, Dote H, Kikuchi T, Toyota M, 
Ouchida M, Aoe M, Date H, Pass HI, Doihara H, Shimizu N (2004). Abberant 
methylation of p57kip2 gene in lung and breast cancers and malignant 
mesotheliomas. Oncol Rep 12: 1087-1092. 
Running title: 
p57Kip2 status predicts carboplatin sensitivity 
 24 
 
Larson PS, Schlechter BL, King CL, Yang Q, Glass CN, Mack C, Pistey R, de las 
Morenas A, Rosenberg CL (2008). CDKN1C/p57kip2 is a candidate tumor 
suppressor gene in human breast cancer. BMC Cancer; 8: 68 
 
Levesque MA, Katsaros D, Massobrio M, Genta F, Yu H, Richiardi G, Fracchioli 
S, Durando A, Arisio R, Diamandis EP (2000). Evidence for a dose-response 
effect between p53 (but not p21waf1/cip1) protein concentrations, survival and 
responsiveness in patients with epithelial ovarian cancer treated with platinum-
based chemotherapy. Clin Cancer Res 6: 3260-3270. 
 
Ma Y, Cress WD (2007). Transcriptional upregulation of p57(Kip2) by the cyclin 
dependent  kinase inhibitor BMS-387032 is E2F dependent and serves as a 
negative feedback loop limiting cytotoxicity. Oncogene 24: 3532-40. 
 
Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone 
A, Cittadini A, Mancuso S, Scambia G, Giordano A (1999).Frequent loss of 
expression of the cyclin-dependent  epithelial  kinase inhibitor p27 in epithelial 
ovarian cancer. Cancer Res 59: 3790-3794. 
 
Roeb W, Boyer A, Cavanee WK, Arden KC (2007). PAX3-FOX01 controls 
expression of the p57kip2 cell cycle regulator through degradation of EGR1. Proc 
Natl Acad Sci 104: 18085-18090. 
Rosenberg E, Demopoulos RI, Zeleniuch-Jacquotte A, Yee H, Sorich J, Speyer 
JL, Newcomb EW (2001). Expression of cell cycle regulators p57kip2, cyclin D1 
Running title: 
p57Kip2 status predicts carboplatin sensitivity 
 25 
and cyclin E in epithelial ovarian tumors and survival. Human Pathol 32: 808-
813. 
Song I-S, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT (2004). Role of 
human copper transporter Ctr1 in the transport of platinum-based antitumour 
agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3: 
1543-1549. 
Syed N, Smith P, Sullivan A, Spender LC, Dyer M, Karran L, O’Nions, Allday M, 
Hoffmann, Crawford D, Griffin B, Farrell PJ, Crook T (2006) Transcriptional 
silencing of polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell 
malignancies Blood 107: 250-6. 
Syed N, Coley HM, Sehouli J, Koensgen D, Mustea A, Szlosarek P, McNeish I, 
Blagden SP, Scmid P, Lovell DP, Hatzmichael, Crook T (2011). Polo-like kinase 
PLK2 is an epigenetic determinant of chemosensitivity and clinical outcomes in 
ovarian cancer. Cancer Research 71: 3317-27.  
Vlachos P, Nyman U, Haji N and Joseph B (2007). The cell cycle inhibitor p57kip2 
promotes cell death via the mitochondrial apoptotic pathway. Cell Death and 
Differentiation 14: 1497-1507. 
 
Wei SH, Chen C-M, Strathdee G, Harnsomburana J, Shyu C-R, Rahmatpanah F, 
Shi H, Ng S-W, Yan PS, Nephew KP, Brown R and Huang  TMH (2002). 
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes 
progression free survival in patients and identifies candidate epigenetic markers. 
Clin Ca Res  8: 2246-52. 
Running title: 
p57Kip2 status predicts carboplatin sensitivity 
 26 
 
Zhang P, Wong C, DePinho RA, Harper JW, Elledge SJ (1998). Cooperation 
between the CDK inhibitors p27kip1 and p57kip2 in control of tissue growth and 
development.  Genes and Development 12: 3162-3167. 
 
 
 
Legends to Figures: 
Figure 1: A: Western immunoblotting of PEO1 cell lines without and with 5-aza-2-
deoxy-cytidine/trichostatin A treatment (+ Aza) using SDS-PAGE gels (NOVEX 
system, Invitrogen, Paisley, UK) followed by western transfer onto PVDF 
membranes. Membranes were probed with a primary rabbit polyclonal antibody to 
p57kip2 sc-8298 (clone H-91) (Santa Cruz, distributors Autogen Bioclear, Calne, UK). 
Membranes were stripped and reprobed for actin as a loading control.  
B: Expression levels of mRNA p57Kip2 in the PEO1 panel of cell lines obtained 
quantitative PCR with SyBr green and actin as the internal control. Data shown are 
the mean (and standard deviation) for at least 3 repeat experiments.  
 
Figure 2: A Dose response curves for PEO1 (circle), PEO1CisR (triangle) and 
PEO1CarbR (square) treated with seliciclib (n =>3, with the standard deviation shown 
for each data point (drug concentration used) as error bars). 
B: IC50 data obtained from dose response curves (using MTT) with continuous drug 
exposure for PEO1 parental (black), PEO1CarbR (vertical shading), PEO1CarbR- 
demethylated (white) and PEO1CisR (horizontal shading) for carboplatin and for 
seliciclib treatments. All experiments were carried out on at least 3 separate occasions 
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and data show the IC50 as mean with standard deviation as error bars,. P values 
obtained for comparison of IC50 values for PEO1CarbR cells versus PEO1CarbR-
demethylated cells were 0.0055 (*) for carboplatin and 0.016 (**) for seliciclib 
(paired t-est). For carboplatin the resistance factors obtained for PEO1CarbR was 4.2 
and for PEO1CarbR-demethylated was 2.2. 
 
Figure 3: Cell cycle analysis for PEO1 cell lines treated with seliciclib (25 µM) for 
48h. Key: SubG1 white, G1 black, S-phase gray, G2M horizontal line. N = 3 separate 
experiments. Cells were stained with PI (see Methods) and analysed used a Coulter 
Epics flow cytometer with data analysis using MultiCycle software (Beckman Corp). 
The S-phase for treated PEO1CarbR cells versus control gave a p value of 0.03, 
indicated as * . 
 
Figure 4: 
A: MSP analysis for PEO1 and PEO1CarbR lines in the absence or presence of 
azacytidine (+aza) for the unmethylated portion (U) and for the methylated portion 
(M). Results shown are typical for those obtained in replicate experiments (n=4). 
B: Pyrosequencing for detection and quantitation of methylation in the promoter 
region of the p57Kip2 gene with extent of methylation obtained from pyrosequencing 
analysis shown on the y axis. 
 
Figure 5: 
A: shows data obtained for PEO1 cells: control (using irrelevant siRNA, experimental 
control set) with carboplatin 100 µM and seliciclib 25uM for 48h. PEO1 cells silenced 
with siRNA to p57Kip2 and drug treated as for control sample set. The lower left hand 
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of the quadrant indicates the live cell population (i.e. PI and FITC negative), with 
various stages of apoptosis being observed in the others as upper left quadrant: PI 
positive (necrotic and/or end stage apoptosis), upper right PI and FITC positive 
mid/late stage apoptosis, lower right FITC only positive – early stage apoptosis. The 
percentage viability shown for each drug treatment indicates the viability expressed as 
a percentage of the control cells (considered as 100%). Numbers are shown as the 
mean and standard deviation for 3 repeat experiments. P value obtained for 
comparison of control seliciclib treated cells versus p57kip2 transfected seliciclib 
treated cells was 0.0085 (using a paired t-test).. 
B: Indicates efficient knock-down of P57KIP2 following siRNA transfection assessed 
using RT-PCR. 
C Flow cytometry data obtained using the annexin assay (as in 5A) with bar graph 
data depicting viability ( obtained from the annexin V/PI negative readout) expressed 
as a percentage of the control untreated cells for treatment with carboplatin at 100, 
150 and 200µM.  * A paired t-test gave p values of 0.007, 0.012 and 0.007 for 100, 
150 and 200µM respectively, when comparing control (irrelevant SiRNA) with 
corresponding result obtained for SiRNA p57kip2 transfected cells 
 
Figure 6: 
A: Scatterplot of mRNA p57kip2 expression levels plotted against length of survival 
showing association with differences in response to treatment as indicated by 
symbols. A significant difference between responses (CR versus PR and NR 
combined) for p57kip2 level p = 0.034 using a one-way ANOVA. 
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